LGALS9 and neoplasm: Binding of galectin 9 (LGALS9) expressed on EVs derived from glioblastoma multiforme (GBM) cells to the TIM3 receptor of DCs affects antigen recognition, processing and presentation, leading to inhibition of cytotoxic T cell-mediated anti-tumor responses [85].